AzTrials
AzTrials

Haematological MalignancyPhase 2/3DETERMINENCT07440290

DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

A Phase 2/3 study testing Dabrafenib and Trametinib in people with Haematological Malignancy and Malignant Neoplasm, run by Cancer Research UK at 27 sites in United Kingdom.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in children with glioma (a type of brain tumour). Read more about this study

Who is it for?
Ages 1 year and older
What is being tested?
Dabrafenib and Trametinib
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
27 sitesUnited Kingdom
Study dates
1 Apr 2026to Oct 2029
Phase
Phase 2/3

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 year and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Confirmed diagnosis of a malignancy harbouring an oncogenic alteration in BRAF V600, including Langerhans cell histiocytosis, using an analytically validated next-generation sequencing method.
  • Patients ≥1 year old and ≥8 kg in body weight.
  • Women of childbearing potential are eligible provided that they meet the following criteria:
  • Have a negative serum or urine pregnancy test before enrolment and;
  • Agree to use one form of a non-hormonal highly effective contraception method (a method that can achieve a failure rate of <1% when used consistently and correctly; the requirement for non-hormonal method is because dabrafenib may decrease the efficacy of oral or any systemic hormonal contraceptives), such as: i. intrauterine device (IUD), ii. bilateral tubal occlusion, bilateral tubal ligation (at least six weeks before taking trial treatment), iii. vasectomised partner, iv. total sexual abstinence. Effective from the first administration of dabrafenib and trametinib (whichever is first), throughout the trial and for two weeks following discontinuation of dabrafenib and for 16 weeks following discontinuation of trametinib (whichever is later).
  • Patients who are breastfeeding must be willing to discontinue breastfeeding from the start of treatment, throughout the trial and for two weeks following discontinuation of dabrafenib and for 16 weeks following discontinuation of trametinib (whichever is later).
Show all 14Show fewer
  • Male patients with partners who are women of childbearing potential are eligible provided that they agree to the following, from the first administration of dabrafenib and trametinib (whichever is first), throughout the trial and for two weeks after the last administration of dabrafenib and 16 weeks after the last administration of trametinib (whichever is later):
  • Agree to take measures not to father children by using a barrier method of contraception (male condom plus spermicide) or to sexual abstinence.
  • Non-vasectomised male partners with partners who are women of childbearing potential should also be advised of the benefit for their partner of using a highly effective method of contraception, such as:
  • combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation [oral, intravaginal or transdermal]), ii. progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), iii. IUD, iv. intrauterine hormone-releasing system (IUS), v. bilateral tubal occlusion, vi. total sexual abstinence.
  • Male patients with pregnant or breastfeeding partners must be advised to use barrier method contraception (male condom) to prevent drug exposure of the foetus or neonate, even if vasectomised.
  • Male patients must refrain from donating sperm for the same period.
  • Patients must be able and willing to undergo a fresh tissue biopsy at baseline and blood samples for translational research. Note that for patients with haematological malignancies or neuroblastomas, blood, bone marrow aspiration and/or trephine or lymph node biopsy samples may be taken.
  • Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol. These measurements should be performed to confirm the patient's eligibility

Who cannot join

  • Diagnosis of one of the following BRAF V600E mutation-positive cancers:
  • Colorectal cancer in adult (≥18 years) patients;
  • Unresectable or metastatic melanoma in adult (≥18 years) patients;
  • Advanced non-small cell lung cancer in adult (≥18 years) patients;
  • Gliomas harbouring a BRAF V600E mutation in paediatric (1 to <16 years) or TYA (16 to <18 years) patients.
  • Previous treatment with dabrafenib and trametinib in combination (or other BRAF and MEK inhibitors in combination) for the current indication.
Show all 23Show fewer
  • Female patients who are pregnant, breastfeeding or planning to become pregnant during the trial or for two weeks following their last dose of dabrafenib or 16 weeks following their last dose of trametinib, whichever is later.
  • Known hypersensitivity to dabrafenib or trametinib or any of the excipients. See the current relevant SmPCs (UK) for the full lists.
  • Patients with a history of retinal vein occlusion.
  • Any impairment of gastrointestinal (GI) function of uncontrolled GI disease that may significantly alter the administration or absorption of dabrafenib and/or trametinib (e.g. history of diverticulitis, metastases to the GI tract, uncontrolled Crohn's disease, uncontrolled ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome or short gut syndrome).
  • Clinically significant cardiac or cerebrovascular disease as defined by:
  • Unstable angina within three months prior to screening;
  • Myocardial infarction within three months prior to screening;
  • History of documented congestive heart failure (New York Heart Association functional classification III/IV) etc.
  • Patients with a cerebrovascular event (including stroke or transient ischaemic attack [TIA]) within three months prior to screening.
  • Patients with primary central nervous system (CNS) tumours may be considered unless intratumoural bleeding has occurred within two weeks prior to the first dose of dabrafenib and trametinib, and patients with punctate CNS haemorrhages <3 mm may be considered.
  • Patients who were administered a live, attenuated vaccine within 28 days prior to initiation of treatment, or anticipation of need for such a vaccine during investigational medicinal product (IMP) treatment or within six months after the final dose of dabrafenib and trametinib.
  • Known active infections (bacterial, fungal or viral) that would interfere with the assessment of safety or efficacy of dabrafenib and trametinib including human immunodeficiency virus (HIV) positivity. Patients with history of testing positive for HIV infection are eligible provided that each of the following conditions are met:
  • CD4 count ≥350/µL;
  • Undetectable viral load;
  • Receiving antiretroviral therapy (ART) that does not interact with IMP (patients should be on established ART for at least four weeks); and
  • No HIV/acquired immune deficiency syndrome associated opportunistic infection in the last 12 months.
  • Any clinically significant concomitant disease or condition (or its treatment) that could interfere with the conduct of the trial (including absorption of oral medications) that would, in the opinion of the Investigator, pose an unacceptable risk to the patient in this trial.

Trial locations and contacts

27 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Aida Sarmiento Castro contact

+44 207 242 0200

determine@cancer.org.uk

27 sites in 1 country

United Kingdom27 sites, 27 recruiting
  • Belfast City Hospital

    Belfast, BT9 7AB

    Vicky Coyle, Prof, V.Coyle@qub.ac.uk

    Not yet recruiting
  • University Hospital Birmingham

    Birmingham, B15 2TT

    Gary Middleton, Prof, +44 (0)121 371 3573, G.Middleton@bham.ac.uk

    Not yet recruiting
  • Birmingham Children's Hospital

    Birmingham, B4 6NH

    Gerard Millen, Dr, +44 (0)7921843607, G.Millen@nhs.net

    Not yet recruiting
  • Bristol Royal Hospital for Children

    Bristol, BS2 8BJ

    Antony Ng, Dr, +44 (0)117 342 8044, Antony.Ng@uhbw.nhs.uk

    Not yet recruiting
  • Bristol Haematology and Oncology Centre

    Bristol, BS2 8ED

    Antony Ng, Dr, +44 (0)117 342 8044, Antony.Ng@uhbw.nhs.uk

    Not yet recruiting
  • Addenbrooke's Hospital

    Cambridge, CB2 OQQ

    Bristi Basu, Dr, +44 (0)1223 596105, Bristi.Basu@nhs.net

    Not yet recruiting
  • Velindre Cancer Centre

    Cardiff, CF14 2TL

    Robert Jones, Dr, +44 (0)2920 615888 ext. 6327, Robert.Hugh.Jones@wales.nhs.uk

    Recruiting
  • Cardiff Children's Hospital

    Cardiff, CF14 4XW

    Madeline Adams, Dr, +44 (0)292 184 2285, Madeline.Adams@wales.nhs.uk

    Recruiting
  • Western General Hospital

    Edinburgh, EH4 2XU

    Stefan Symeonides, Dr, +44 (0)131 651 8500, Stefan.Symeonides@ed.ac.uk

    Recruiting
  • The Beatson Hospital

    Glasgow, G12 OYN

    Patricia Roxburgh, Dr, +44 (0)141 301 7118, Patricia.Roxburgh@glasgow.ac.uk

    Not yet recruiting
  • Royal Hospital for Children Glasgow

    Glasgow, G51 4TF

    Milind Ronghe, Dr, +44 (0)141 452 6692, Milind.Ronghe@ggc.scot.nhs.uk

    Recruiting
  • Leicester Royal Infirmary

    Leicester, LE1 5WW

    Harriet Walker, Dr, +44 (0)116 258 7602, Harriet.Walter1@nhs.net

    Recruiting
  • Alder Hey Hospital

    Liverpool, L14 5AB

    Lisa Howell, Dr, +44 (0)151 293 3679, Lisa.Howell@alderhey.nhs.uk

    Not yet recruiting
  • University College London Hospital

    London, NW1 2BU

    Martin Foster, Prof, +44 (0)20 3447 5085, M.Forster@ucl.ac.uk

    Recruiting
  • Guy's Hopsital

    London, SE1 9RT

    James Spicer, Dr, +44 (0)20 7188 4260, James.Spicer@kcl.ac.uk

    Recruiting
  • Great Ormond Street Hospital

    London, WC1N 3JH

    Darren Hargrave, Dr, +44 (0)207 813 8525, Darren.Hargrave@gosh.nhs.uk

    Not yet recruiting
  • Royal Manchester Children's Hospital

    Manchester, M13 9WL

    Guy Makin, Dr, +44 0161 701 8419, Guy.Makin@mft.nhs.uk

    Not yet recruiting
  • The Christie Hospital

    Manchester, M20 4BX

    Matthew Krebs, Prof, +44 (0)161 918 7672, Matthew.Krebs@nhs.net

    Recruiting
  • Clatterbridge Cancer Centre

    Metropolitan Borough of Wirral, CH63 4JY

    Dan Palmer, Dr, +44 151 706 4172/ 151 706 4177, Daniel.Palmer@liverpool.ac.uk

    Recruiting
  • Great North Children's Hospital

    Newcastle, NE1 4LP

    Alastair Greystoke, Dr, +44 (0)191 2138476, Alastair.Greystoke@newcastle.ac.uk

    Recruiting
  • Freeman Hospital

    Newcastle, NE7 7DN

    Alastair Greystoke, Dr, +44 (0)191 2138476, Greystoke@newcastle.ac.uk

    Recruiting
  • Churchill Hospital

    Oxford, OX3 7LE

    Sarah Pratap, Dr, +44 (0)1865 235273, Sarah.Pratap@ouh.nhs.uk

    Recruiting
  • John Radcliffe Hospital

    Oxford, OX3 9DU

    Sarah Pratap, Dr, +44 (0)1865 235273, Sarah.Pratap@ouh.nhs.uk

    Recruiting
  • Weston Park Hospital

    Sheffield, S10 2SJ

    Sarah Danson, Dr, +44 (0)114 226 5068, S.Danson@sheffield.ac.uk

    Not yet recruiting
  • Sheffield's Children's Hospital

    Sheffield, S10 2TH

    Daniel Yeomanson, Dr, +44 (0)114 271 7366, danyeomanson@nhs.net

    Not yet recruiting
  • Southampton General Hospital

    Southampton

    Juliet Gray, Prof, +44 (0)238 120 6639, Juliet.Gray@uhs.nhs.uk

    Recruiting
  • The Royal Marsden Hospital

    Sutton, SM2 5PT

    Lynley Marshall, Dr, +44 (0)208 661 3678, LynleyVanessa.Marshall@icr.ac.uk

    Recruiting

Other trials in United Kingdom

About this study

Official title: DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and TYA Patients With BRAF V600 Mutation-Positive Cancers.

This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in children with glioma (a type of brain tumour). This means they have gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Dabrafenib and trametinib work in patients with a particular mutation in their cancer known as BRAF V600.

Investigators now wish to find out if they will be useful in treating patients with other cancer types which have the same mutation. If the results are positive, the study team will work with the NHS and the Cancer Drugs Fund to see if these drugs can be routinely accessed for patients in the future.

This trial is part of a trial programme called DETERMINE. The programme will also look at other anti-cancer drugs in the same way, through matching the drug to rare cancer types or ones with specific mutations.

Read the detailed description

DETERMINE Treatment Arm 07 (dabrafenib and trametinib) aims to evaluate the efficacy of dabrafenib and trametinib adult, paediatric and TYA patients with rare* cancers with BRAF V600 mutations or with common cancers where BRAF V600 mutations are considered to be infrequent.

*Rare is defined generally as incidence less than 6 cases in 100,000 patients (includes paediatric and teenagers/young adult cancers) or common cancers with rare alterations.

This treatment arm has a target sample size of 30 evaluable patients. Sub-cohorts may be defined and further expanded to a target of 30 evaluable patients each.

The ultimate aim is to translate positive clinical findings to the NHS (Cancer Drugs Fund) to provide new treatment options for rare adult, paediatric and TYA cancers.

OUTLINE:

Pre-screening: The Molecular Tumour Board makes a treatment recommendation for the patient based on molecularly-defined cohorts (See information on Master Screening Protocol below).

Screening: Consenting patients undergo biopsy and collection of blood samples for research purposes.

Treatment: Patients will receive dabrafenib and trametinib until disease progression without clinical benefit, unacceptable adverse events (AEs) or withdrawal of consent. Patients will also undergo collection of blood samples at various intervals while receiving treatment and at End of Treatment (EoT).

After completion of study treatment, patients are followed up every 3 months for 2 years.

THE DETERMINE TRIAL MASTER (SCREENING) PROTOCOL: Please see DETERMINE Trial Master (Screening) Protocol record (NCT05722886) for information on the DETERMINE Trial Master Protocol and applicable documents.

Being tested
Dabrafenib, Trametinib
Keywords
Adult, Antineoplastic Agents, Cancer, Child, Dabrafenib, Malignancy, Malignant Neoplasms, Molecular Targeted Therapy, Mutation, Neoplasms by Histologic Site, Neoplasms by Site, Paediatric, Precision Medicine, Proto-Oncogene Proteins B-raf, Protein Kinase Inhibitors, Rare, Trametinib, Tumour-Agnostic, Young adult
Medical subject headings
Hematologic Neoplasms, Neoplasms, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Gastrointestinal Neoplasms, Histiocytosis, Langerhans-Cell, Erdheim-Chester Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DabrafenibDrug

    Also called Tafinlar, Finlee

    Adult patients (≥18 years) will receive dabrafenib at a dose of 150 mg (two 75 mg tablets) twice daily (total daily dose 300 mg) throughout each 28-day cycle.

    Paediatric patients (1 to <12 years) will receive dabrafenib dose adjusted by body weight as 10 mg dispersible tablets orally twice daily throughout each 28-day cycle.

    Paediatric patients (12-15 years) and TYA patients (16 to <18 years) will have the option to receive adult or paediatric dosing.

    Patients may continue until disease progression without clinical benefit, unacceptable AEs or withdrawal of consent.

  • TrametinibDrug

    Also called Mekinist, Spexotras

    Adult patients (≥18 years) will receive trametinib at a daily dose of 2 mg (one 2 mg tablet) orally once daily (total daily dose 2 mg) throughout the 28-day cycle.

    Paediatric patients (1 to <12 years) receive trametinib at a dose adjusted by body weight as 0.05 mg/m^2 powder for oral solution once daily throughout each 28-day cycle.

    Paediatric patients (12-15 years) and TYA patients (16 to <18 years) will have the option to receive adult or paediatric dosing.

    Patients may continue until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent.

Study groups in NCT07440290
Study groupRoleWhat they receive
Treatment Arm 07: Dabrafenib and TrametinibExperimentalThis dabrafenib and trametinib treatment arm is for adult, paediatric and TYA patients with cancers harbouring BRAF V600 mutations.
Receives: Drug: Dabrafenib; Drug: Trametinib

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Objective response (OR)

    OR is defined as the confirmed occurrence of either a complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 criteria (or immune [i]RECIST or standard imaging criteria for specific disease e.g. Response Evaluation in Neuro Oncology criteria [RANO]). In patients with leukaemia, OR will be defined as the occurrence of CR, CRi (CR with incomplete neutrophil recovery) or CRp (CR with incomplete platelet recovery). The trial will report the proportion of patients with an OR and 95% credible interval.

    Measured: Disease assessments to be performed up to 24 weeks from the start of trial treatment.

  2. Durable Clinical Benefit (DCB)

    DCB is defined as the absence of disease progression for at least 24 weeks from the start of trial treatment according to RECIST Version 1.1 criteria (or iRECIST or standard imaging criteria for specific disease e.g. RANO criteria) and, where relevant (e.g. for haematological malignancies), by standard bone marrow response criteria. Alternative definitions of DCB based on different time points may be pre-specified for particular sub-cohorts if 24 weeks is not clinically relevant. The trial will report the proportion of patients with a DCB and 95% credible interval.

    Measured: Disease assessments to be performed up to 24 weeks from the start of trial treatment.

Secondary outcomes (13)
  1. Duration of response (DR)

    DR is defined as the time from the date of the first confirmed CR or PR according to RECIST Version 1.1 criteria (or iRECIST) or standard imaging criteria for specific disease. The trial will report the median DR and 95% credible interval.

    Measured: Disease assessment performed every 2 cycles (each cycle is 28 days) and at EoT. After 24 weeks, it can be done every 12 weeks, on discussion with Sponsor. Follow-up visits are every 3 months after last dose, for up to 2 years.

  2. Best percentage change in sum of target lesion/index lesion diameters (PCSD)

    PCSD is defined as the greatest decrease or least increase in the sum of target lesion diameters (RECIST) or index lesion diameters (iRECIST) as a percentage compared to the baseline measurement. The trial will report the mean PCSD and 95% credible interval.

    Measured: Disease assessment performed every 2 cycles (each cycle is 28 days) and at EoT. After 24 weeks, it can be done every 12 weeks, on discussion with Sponsor. Follow-up visits are every 3 months after last dose, for up to 2 years.

  3. Time to treatment discontinuation (TTD)

    TTD is defined as the time from date of starting trial treatment to date of discontinuing trial treatment, in days estimated by the median of the posterior inverse gamma probability distribution. The trial will report the median TTD and 95% credible interval.

    Measured: From first dose of dabrafenib and trametinib to discontinuation of trial treatment up to 5 years.

  4. Progression-Free Survival time (PFS)

    PFS is defined as the time from date of starting trial treatment to date of progression or date of death without a previous progression recorded estimated by the median of the posterior inverse gamma probability distribution.

    Measured: Disease assessment performed every 2 cycles (each cycle is 28 days) and at EoT. After 24 weeks, it can be done every 12 weeks, on discussion with Sponsor. Follow-up visits are every 3 months after last dose, for up to 2 years.

  5. Time to Progression (TTP)

    TTP is defined as the time from date of starting trial treatment to date of progression or date of death without recorded progression censored rather than events. The trial will report the median TTP and 95% credible interval.

    Measured: Disease assessment performed every 2 cycles (each cycle is 28 days) and at EoT. After 24 weeks, it can be done every 12 weeks, on discussion with Sponsor. Follow-up visits are every 3 months after last dose, for up to 2 years.

  6. Growth Modulation Index (GMI)

    GMI is defined as the ratio of TTP with the trial protocol treatment to TTP on the most recent prior line of therapy. The trial will report the mean GMI and 95% credible interval.

    Measured: Disease assessment performed every 2 cycles (each cycle is 28 days) and at EoT. After 24 weeks, it can be done every 12 weeks, on discussion with Sponsor. Follow-up visits are every 3 months after last dose, for up to 2 years.

  7. Overall Survival time (OS)

    OS is defined as the time from date of starting trial treatment to date of death from any cause estimated by the median of the posterior normal probability distribution.

    Measured: Time of death or up to 2 years after the EoT visit.

  8. Occurrence of at least one Suspected Unexpected Serious Adverse Reaction (SUSAR)

    The trial will report the number of patients who experience at least one SUSAR to dabrafenib or trametinib.

    Measured: From the time of consent until 28 days after last dose of dabrafenib or trametinib (up to 5 years) or until patient starts another anti-cancer therapy, whichever came first. An average time frame will be presented with results entry.

  9. Occurrence of at least one Grade 3, 4 or 5 dabrafenib and/or trametinib related AE

    Number of patients who experience at least one dabrafenib and trametinib related Grade 3, 4 or 5 AE according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.

    Measured: From the time of consent until 28 days after last dose of dabrafenib and/or trametinib (up to 5 years) or until patient starts another anti-cancer therapy, whichever came first. An average time frame will be presented with results entry.

  10. EORTC-QLQ-30-Standardised Area Under Summary Score Curve (QLQSAUC) in adult patients

    For adult patients, multiple measures of Quality of Life (QoL) will be generated from patient completion of the European Organisation for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) questionnaire (15 measures). For each patient the Summary Score from the questionnaire will be generated at each time point and the area under the curve generated by these scores over time will be calculated and standardised by the time frame. The trial will report the mean QLQSAUC and 95% credible interval.

    Measured: QoL surveys performed prior to inclusion, every cycle (each cycle is 28 days) and at EoT visit (up to 5 years).

  11. EQ-5D Standardised Area Under Index Value Curve (EQ5DSAUC) in adult patients

    For adult populations, two measures of QoL will be generated from patient completion of the EQ-5D-5L questionnaire. For each measure, scores based on responses from the questionnaire will be generated at each time point and the area under the curve generated by these scores over time will be calculated and standardised by the time frame. The trial will report the mean EQ5DSAUC and 95% credible interval.

    Measured: QoL surveys performed prior to inclusion, every cycle (each cycle is 28 days) and at EoT visit (up to 5 years).

  12. Mean change from baseline in the PedsQL 4.0 Standardised Area Under Total Scale Score Curve (PedSAUC) in paediatric patients

    For paediatric populations, multiple measures of QoL will be generated from patient completion of the PedsQL 4.0 (4 measures). The Summary Score from the questionnaire will be generated at each time point and the area under the curve generated by these scores over time will be calculated and standardised by the time frame. The trial will report the mean PedSAUC and the 95% credible interval.

    Measured: QoL surveys performed prior to inclusion, every cycle (each cycle is 21 days) and at EoT visit (up to 5 years).

  13. Mean change from baseline in the PedsQL 4.0 Standardised Area Under total Scale Score Curve (PedsSAUC) in parents of paediatric patients

    For paediatric populations, multiple measures of QoL will be generated from patient's parent completion of the PedsQL 4.0 (4 measures). The Summary Score from the questionnaire will be generated at each time point and the area under the curve generated by these scores over time will be calculated and standardised by the time frame. The trial will report the mean PedSAUC and the 95% credible interval.

    Measured: QoL surveys performed prior to inclusion, every cycle (each cycle is 21 days) and at EoT visit (up to 5 years).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Feb 2026
  2. Study start1 Apr 2026
  3. Primary completionOct 2029 (estimated)
  4. Study completionOct 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2/3
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07440290
Sponsor's protocol ID
CRUKD/21/004 - Treatment Arm 7
Acronym
DETERMINE
Status last verified
Aug 2026
First submitted
23 Feb 2026
Last updated
17 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Individual de-identified patient data will be shared with researchers whose proposed use of the data is approved by a review committee of the Sponsor. Supporting Information: Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF)

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in